BRAINSTORM CELL THERAPEUTICS (BCLI)
US10501E2019 - Common Stock
| 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 1.30M | 770.00K | 18.86M | 37.83M | 540.00K | |||
| Marketable Securities | 0.00 | 2.21M | 3.24M | 4.11M | 30.00K | |||
| Receivables | 51.00K | 90.00K | 90.00K | 300.00K | 2.36M | |||
| Other Current Assets | 548.00K | 30.00K | 1.10M | 1.00M | 440.00K | |||
| Total Current Assets | 1.90M | 3.11M | 23.28M | 43.24M | 3.36M | |||
| Non-Current Assets | ||||||||
| PPE Net | 2.10M | 5.32M | 5.97M | 7.99M | 3.14M | |||
| Other Non-Current Assets | 207.00K | 20.00K | 30.00K | 30.00K | 30.00K | |||
| Total Non-Current Assets | 2.31M | 5.34M | 6.00M | 8.02M | 3.17M | |||
| TOTAL ASSETS | 4.21M | 8.45M | 29.28M | 51.26M | 6.53M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | N/A | N/A | N/A | N/A | N/A | |||
| Accrued Expenses | 1.84M | 1.51M | 1.54M | 3.92M | 2.26M | |||
| Accounts Payable | 4.95M | 6.22M | 3.70M | 5.42M | 14.68M | |||
| Other Current Liabilities | 1.00M | 1.07M | 1.07M | 1.90M | 710.00K | |||
| Total Current Liabilities | 7.80M | 8.80M | 6.32M | 11.23M | 17.65M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Non-Current Liabilities | 1.27M | 2.67M | 3.62M | 4.56M | 1.10M | |||
| Total Non-Current Liabilities | 1.27M | 2.67M | 3.62M | 4.57M | 1.11M | |||
| TOTAL LIABILITIES | 9.07M | 11.47M | 9.94M | 15.80M | 18.76M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -215.01M | -197.82M | -173.54M | -149.09M | -117.28M | |||
| Additional Paid In Capital | 210.26M | 194.91M | 192.99M | 184.66M | 105.04M | |||
| Common Shares | 13.00K | 10.00K | 10.00K | 10.00K | 10.00K | |||
| Treasury Stock | -116.00K | -120.00K | -120.00K | -120.00K | N/A | |||
| Other Shareholders' Equity | N/A | N/A | N/A | N/A | 0.00 | |||
| Shares Outstanding | 60.49M | 36.69M | 36.40M | 35.16M | 23.17M | |||
| Tangible Book Value per Share | -0.08 | -0.08 | 0.53 | 1.01 | -0.53 | |||
| Total Shareholders' Equity | -4.86M | -3.02M | 19.34M | 35.46M | -12.22M | |||
| TOTAL LIABILITIES AND EQUITY | 4.21M | 8.45M | 29.28M | 51.26M | 6.53M | |||
| Statistics | ||||||||
| Current Ratio | 0.24 | 0.35 | 3.68 | 3.85 | 0.19 | |||
| Return On Assets (ROA) | -408.56% | -287.34% | -83.54% | -62.06% | -356.05% | |||
| Return On Equity (ROE) | N/A | N/A | -126.47% | -89.71% | N/A | |||
All data in USD